Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS-6779
- Development stage
- Phase 1
- Lead developer
- Gilead Sciences
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GS-6779 is a nonreplicating arenavirus vector therapeutic vaccine developed for the treatment of chronic Hepatitis B (CHB). It is designed to stimulate the immune system to target and clear the Hepatitis B virus. The drug is administered intramuscularly and is currently being evaluated in a Phase 1a/1b clinical study to assess its safety and tolerability in healthy participants and those with chronic Hepatitis B. Initially developed through a collaboration between HOOKIPA Pharma and Gilead Sciences, the program was later fully acquired by Gilead Sciences, which is now solely responsible for its further development and commercialization.
02
Targets
HBV antigens (Hepatitis B virus antigens)
Beyond the preview
Go deeper on GS-6779.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS-6779.